JP2018507914A - 非アルコール性脂肪肝疾患および／またはリポジストロフィーの処置のための方法 - Google Patents

非アルコール性脂肪肝疾患および／またはリポジストロフィーの処置のための方法 Download PDF

Info

Publication number
JP2018507914A
JP2018507914A JP2017566609A JP2017566609A JP2018507914A JP 2018507914 A JP2018507914 A JP 2018507914A JP 2017566609 A JP2017566609 A JP 2017566609A JP 2017566609 A JP2017566609 A JP 2017566609A JP 2018507914 A JP2018507914 A JP 2018507914A
Authority
JP
Japan
Prior art keywords
lipodystrophy
nafld
formula
compound
amount
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017566609A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018507914A5 (enExample
Inventor
マンツォロス，クリストス
Original Assignee
インテクリン・セラピューティクス・インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by インテクリン・セラピューティクス・インコーポレイテッド filed Critical インテクリン・セラピューティクス・インコーポレイテッド
Publication of JP2018507914A publication Critical patent/JP2018507914A/ja
Publication of JP2018507914A5 publication Critical patent/JP2018507914A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2017566609A 2015-03-09 2016-03-07 非アルコール性脂肪肝疾患および／またはリポジストロフィーの処置のための方法 Pending JP2018507914A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562130488P 2015-03-09 2015-03-09
US62/130,488 2015-03-09
PCT/US2016/021162 WO2016144862A1 (en) 2015-03-09 2016-03-07 Methods for the treatment of nonalcoholic fatty liver disease and/or lipodystrophy

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020209008A Division JP2021063088A (ja) 2015-03-09 2020-12-17 非アルコール性脂肪肝疾患および／またはリポジストロフィーの処置のための方法

Publications (2)

Publication Number Publication Date
JP2018507914A true JP2018507914A (ja) 2018-03-22
JP2018507914A5 JP2018507914A5 (enExample) 2019-06-27

Family

ID=56879272

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2017566609A Pending JP2018507914A (ja) 2015-03-09 2016-03-07 非アルコール性脂肪肝疾患および／またはリポジストロフィーの処置のための方法
JP2020209008A Pending JP2021063088A (ja) 2015-03-09 2020-12-17 非アルコール性脂肪肝疾患および／またはリポジストロフィーの処置のための方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2020209008A Pending JP2021063088A (ja) 2015-03-09 2020-12-17 非アルコール性脂肪肝疾患および／またはリポジストロフィーの処置のための方法

Country Status (16)

Country Link
US (3) US10555929B2 (enExample)
EP (1) EP3267994A4 (enExample)
JP (2) JP2018507914A (enExample)
KR (2) KR20220070057A (enExample)
CN (1) CN107683135A (enExample)
AU (2) AU2016229982B2 (enExample)
BR (1) BR112017019170A2 (enExample)
CA (1) CA2979033A1 (enExample)
EA (1) EA201791982A1 (enExample)
HK (1) HK1249847A1 (enExample)
IL (1) IL254282A0 (enExample)
MA (1) MA42450A (enExample)
MX (2) MX386778B (enExample)
SG (2) SG11201707276PA (enExample)
TW (1) TWI769976B (enExample)
WO (1) WO2016144862A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021063088A (ja) * 2015-03-09 2021-04-22 インテクリン・セラピューティクス・インコーポレイテッド 非アルコール性脂肪肝疾患および／またはリポジストロフィーの処置のための方法

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9719068B2 (en) 2010-05-06 2017-08-01 Children's Hospital Medical Center Methods and systems for converting precursor cells into intestinal tissues through directed differentiation
SG10201801654RA (en) 2014-05-28 2018-04-27 Childrens Hospital Med Ct Methods and systems for converting precursor cells into gastric tissues through directed differentiation
AU2015331848B2 (en) 2014-10-17 2022-03-03 Children's Hospital Medical Center, D/B/A Cincinnati Children's Hospital Medical Center In vivo model of human small intestine using pluripotent stem cells and methods of making and using same
CN109415685B (zh) 2016-05-05 2023-07-04 儿童医院医疗中心 用于体外制造胃底组织的方法和与其相关的组合物
EP3534976A4 (en) 2016-11-04 2020-09-16 Children's Hospital Medical Center PATHOLOGICAL MODELS OF HEPATIC ORGANOIDS AND ASSOCIATED METHODS OF MANUFACTURE AND USE
CA3045145A1 (en) 2016-12-05 2018-06-14 Children's Hospital Medical Center Colonic organoids and methods of making and using same
WO2018187350A1 (en) 2017-04-03 2018-10-11 Coherus Biosciences Inc. PPARγ AGONIST FOR TREATMENT OF PROGRESSIVE SUPRANUCLEAR PALSY
WO2018191673A1 (en) 2017-04-14 2018-10-18 Children's Hospital Medical Center Multi donor stem cell compositions and methods of making same
GB201710229D0 (en) * 2017-06-27 2017-08-09 Tdeltas Ltd Compounds for new use
GB201715654D0 (en) 2017-09-27 2017-11-08 Tdeltas Ltd Method of treatment
JP2020536529A (ja) 2017-10-10 2020-12-17 チルドレンズ ホスピタル メディカル センター 食道組織および／または臓器組成物およびそれを作製する方法
WO2019126626A1 (en) 2017-12-21 2019-06-27 Children's Hospital Medical Center Digitalized human organoids and methods of using same
EP3826652B1 (en) 2018-07-26 2026-02-25 Children's Hospital Medical Center Hepato-biliary-pancreatic tissues and methods of making same
EP3849568A4 (en) 2018-09-12 2022-06-15 Children's Hospital Medical Center Organoid compositions for the production of hematopoietic stem cells and derivatives thereof
GB2577723A (en) 2018-10-04 2020-04-08 Tdeltas Ltd Compounds for new use
JP2022516509A (ja) * 2018-12-31 2022-02-28 コヒラス・バイオサイエンシズ・インコーポレイテッド 非アルコール性脂肪性肝疾患（ｎａｆｌｄ）を治療するための組成物および方法
WO2020205027A1 (en) * 2019-04-02 2020-10-08 Christos Mantzoros Compositions and methods to treat non-alcoholic fatty liver diseases (nafld)
WO2020205025A1 (en) * 2019-04-04 2020-10-08 Coherus Biosciences, Inc. Compositions and methods to treat non-alcoholic fatty liver diseases (nafld)
EP3946334A1 (en) * 2019-04-04 2022-02-09 Coherus Biosciences, Inc. Compositions and methods to treat non-alcoholic fatty liver diseases (nafld)
US20220193065A1 (en) * 2019-04-04 2022-06-23 Coherus Biosciences, Inc. Compositions and methods to treat non-alcoholic fatty liver diseases (nafld)
US20220288054A1 (en) * 2019-04-04 2022-09-15 Coherus Biosciences, Inc. Compositions and methods to treat non-alcoholic fatty liver diseases (nafld)
AU2020283048A1 (en) 2019-05-31 2021-12-23 Children's Hospital Medical Center Shaped organoid compositions and methods of making same
EP3976066A4 (en) 2019-05-31 2023-06-28 Children's Hospital Medical Center Methods of generating and expanding hematopoietic stem cells
WO2021076616A1 (en) * 2019-10-15 2021-04-22 Coherus Biosciences, Inc. Compositions and methods to treat non-alcoholic fatty liver diseases (nafld)
JP2022104747A (ja) * 2020-12-29 2022-07-11 国立研究開発法人国立がん研究センター 抗ウイルス剤
CN118406749A (zh) * 2024-02-29 2024-07-30 安徽医科大学 Caveolin-1基因在制备预防、治疗或缓解非酒精性脂肪肝病的药物中的应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009151116A1 (ja) * 2008-06-13 2009-12-17 持田製薬株式会社 非アルコール性脂肪肝炎の予防／改善・治療薬
JP2013133312A (ja) * 2011-12-27 2013-07-08 Tropical Plant Resources Institute Inc 非アルコール性脂肪性肝疾患および／または非アルコール性脂肪肝炎の治療薬
WO2015005365A1 (ja) * 2013-07-10 2015-01-15 興和株式会社 非アルコール性脂肪性肝疾患治療剤

Family Cites Families (399)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE296075C (enExample)
US4166452A (en) 1976-05-03 1979-09-04 Generales Constantine D J Jr Apparatus for testing human responses to stimuli
US4256108A (en) 1977-04-07 1981-03-17 Alza Corporation Microporous-semipermeable laminated osmotic system
US4265874A (en) 1980-04-25 1981-05-05 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
JPS61100519A (ja) 1984-10-23 1986-05-19 Shin Etsu Chem Co Ltd 医薬用硬質カプセル
US5618920A (en) 1985-11-01 1997-04-08 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
DD296075A5 (de) 1989-08-07 1991-11-21 Martin-Luther-Universitaet Halle-Wittenberg,De Verfahren zur herstellung neuer inhibitoren der dipeptidyl peptidase iv
CA2080474A1 (en) 1990-04-14 1991-10-15 William W. Bachovchin Inhibitors of dipeptidyl-aminopeptidase type iv
US5462928A (en) 1990-04-14 1995-10-31 New England Medical Center Hospitals, Inc. Inhibitors of dipeptidyl-aminopeptidase type IV
EP0940468A1 (en) 1991-06-14 1999-09-08 Genentech, Inc. Humanized antibody variable domain
US6825169B1 (en) 1991-10-22 2004-11-30 Trustees Of Tufts College Inhibitors of dipeptidyl-aminopeptidase type IV
EP0610317B1 (en) 1991-10-22 2001-01-31 New England Medical Center Hospitals, Inc. Inhibitors of dipeptidyl-aminopeptidase type iv
MX9206628A (es) 1991-11-22 1993-05-01 Boehringer Ingelheim Pharma Ester de prolinaboronato y metodo para su preparacion.
US5431917A (en) 1992-10-08 1995-07-11 Japan Elanco Company, Ltd. Hard capsule for pharmaceutical drugs and method for producing the same
US5424286A (en) 1993-05-24 1995-06-13 Eng; John Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same
IL111785A0 (en) 1993-12-03 1995-01-24 Ferring Bv Dp-iv inhibitors and pharmaceutical compositions containing them
US5543396A (en) 1994-04-28 1996-08-06 Georgia Tech Research Corp. Proline phosphonate derivatives
US20020006899A1 (en) 1998-10-06 2002-01-17 Pospisilik Andrew J. Use of dipeptidyl peptidase IV effectors for lowering blood pressure in mammals
DE122010000020I1 (de) 1996-04-25 2010-07-08 Prosidion Ltd Verfahren zur Senkung des Blutglukosespiegels in Säugern
WO1998018763A1 (en) 1996-10-25 1998-05-07 Tanabe Seiyaku Co., Ltd. Tetrahydroisoquinoline derivatives
US6011155A (en) 1996-11-07 2000-01-04 Novartis Ag N-(substituted glycyl)-2-cyanopyrrolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV
TW492957B (en) 1996-11-07 2002-07-01 Novartis Ag N-substituted 2-cyanopyrrolidnes
US5736151A (en) 1996-12-09 1998-04-07 Pharmacia & Upjohn Company Antibiotic oil suspensions
JP4798814B2 (ja) 1997-01-07 2011-10-19 アミリン・ファーマシューティカルズ，インコーポレイテッド 食物摂取低減用のエキセンジンおよびそのアゴニストの使用
KR100870353B1 (ko) 1997-04-07 2008-11-25 제넨테크, 인크. 항-ｖｅｇｆ 항체
US6040145A (en) 1997-05-07 2000-03-21 Tufts University Potentiation of the immune response
US6100234A (en) 1997-05-07 2000-08-08 Tufts University Treatment of HIV
ATE357509T1 (de) 1997-09-29 2007-04-15 Point Therapeutics Inc Stimulierung von hämatopoietischen zellen im vitro
DE69839279T2 (de) 1997-11-18 2009-05-28 Zaidan Hojin Biseibutsu Kagaku Kenkyu Kai Neue physiologisch aktive substanz sulphostin, herstellung und verwendung derselben
US6583157B2 (en) 1998-01-29 2003-06-24 Tularik Inc. Quinolinyl and benzothiazolyl modulators
EP1053227B1 (en) 1998-01-29 2008-11-05 Amgen Inc. Ppar-gamma modulators
EP1520582A3 (en) 1998-02-02 2009-07-01 Trustees Of Tufts College Use of dipeptidylpetidase inhibitors to regulate glucose metabolism
US20020061839A1 (en) 1998-03-09 2002-05-23 Scharpe Simon Lodewijk Serine peptidase modulators
IL139247A0 (en) 1998-05-04 2001-11-25 Point Therapeutics Inc Hematopoietic stimulation
DE19823831A1 (de) 1998-05-28 1999-12-02 Probiodrug Ges Fuer Arzneim Neue pharmazeutische Verwendung von Isoleucyl Thiazolidid und seinen Salzen
NZ508642A (en) 1998-06-05 2003-10-31 Point Therapeutics Inc Cyclic boroproline compounds
DE19828114A1 (de) 1998-06-24 2000-01-27 Probiodrug Ges Fuer Arzneim Produgs instabiler Inhibitoren der Dipeptidyl Peptidase IV
DE19828113A1 (de) 1998-06-24 2000-01-05 Probiodrug Ges Fuer Arzneim Prodrugs von Inhibitoren der Dipeptidyl Peptidase IV
DE19834591A1 (de) 1998-07-31 2000-02-03 Probiodrug Ges Fuer Arzneim Verfahren zur Steigerung des Blutglukosespiegels in Säugern
EP1104293A1 (en) 1998-08-21 2001-06-06 Point Therapeutics, Inc. Regulation of substrate activity
US6242422B1 (en) 1998-10-22 2001-06-05 Idun Pharmacueticals, Inc. (Substituted)Acyl dipeptidyl inhibitors of the ice/ced-3 family of cysteine proteases
JP3449253B2 (ja) 1998-10-29 2003-09-22 シオノギクオリカプス株式会社 硬質カプセルの製造方法
PL205713B1 (pl) 1998-12-07 2010-05-31 Sod Conseils Rech Applic Związki stanowiące analogi GLP-1, kompozycje farmaceutyczne zawierające takie związki oraz zastosowanie tych związków
CN1333746A (zh) 1998-12-09 2002-01-30 拉卓拉药物公司 用作包含氨基甲酸酯键的模版的分子台架
CO5150173A1 (es) 1998-12-10 2002-04-29 Novartis Ag Compuestos n-(glicilo sustituido)-2-cianopirrolidinas inhibidores de peptidasa de dipeptidilo-iv (dpp-iv) los cuales son efectivos en el tratamiento de condiciones mediadas por la inhibicion de dpp-iv
JP2000191616A (ja) 1998-12-24 2000-07-11 Senju Pharmaceut Co Ltd 新規ジペプチジルアルデヒド誘導体およびそれを含有する医薬
EP1140145B2 (en) 1999-01-14 2019-05-15 Amylin Pharmaceuticals, LLC Novel exendin agonist formulations and methods of administration thereof
JP3018186B1 (ja) 1999-03-09 2000-03-13 大阪大学長 抗炎症剤、単球系細胞の増殖抑制剤
GB9906714D0 (en) 1999-03-23 1999-05-19 Ferring Bv Compositions for improving fertility
GB9906715D0 (en) 1999-03-23 1999-05-19 Ferring Bv Compositions for promoting growth
US20050272652A1 (en) 1999-03-29 2005-12-08 Gault Victor A Peptide analogues of GIP for treatment of diabetes, insulin resistance and obesity
JP3716901B2 (ja) 1999-04-14 2005-11-16 シオノギクオリカプス株式会社 セルロースエーテルフィルム
JP4121215B2 (ja) 1999-05-17 2008-07-23 財団法人微生物化学研究会 スルフォスチン類縁体、並びにスルフォスチン及びその類縁体の製造方法
CA2373643A1 (en) 1999-05-25 2000-11-30 Point Therapeutics, Inc. Anti-tumor comprising boroproline compounds
US6107317A (en) 1999-06-24 2000-08-22 Novartis Ag N-(substituted glycyl)-thiazolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV
US6110949A (en) 1999-06-24 2000-08-29 Novartis Ag N-(substituted glycyl)-4-cyanothiazolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV
US6172081B1 (en) 1999-06-24 2001-01-09 Novartis Ag Tetrahydroisoquinoline 3-carboxamide derivatives
CN1171872C (zh) 1999-06-30 2004-10-20 图拉列克股份有限公司 调节PPARγ活性的化合物
US7041691B1 (en) 1999-06-30 2006-05-09 Amgen Inc. Compounds for the modulation of PPARγ activity
US6617340B1 (en) 1999-07-29 2003-09-09 Novartis Ag N-(substituted glycyl)-pyrrolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV
DE19940130A1 (de) 1999-08-24 2001-03-01 Probiodrug Ges Fuer Arzneim Neue Effektoren der Dipeptidyl Peptidase IV zur topischen Anwendung
US6515117B2 (en) 1999-10-12 2003-02-04 Bristol-Myers Squibb Company C-aryl glucoside SGLT2 inhibitors and method
PH12000002657B1 (en) 1999-10-12 2006-02-21 Bristol Myers Squibb Co C-aryl glucoside SGLT2 inhibitors
US20040152745A1 (en) 1999-11-12 2004-08-05 Guilford Pharmaceuticals, Inc. Dipeptidyl peptidase IV inhibitors and methods of making and using dipeptidyl peptidase IV inhibitors
CA2390231A1 (en) 1999-11-12 2001-05-17 Paul Jackson Dipeptidyl peptidase iv inhibitors and methods of making and using dipeptidyl peptidase iv inhibitors
GB9928330D0 (en) 1999-11-30 2000-01-26 Ferring Bv Novel antidiabetic agents
US6380398B2 (en) 2000-01-04 2002-04-30 Novo Nordisk A/S Therapeutically active and selective heterocyclic compounds that are inhibitors of the enzyme DPP-IV
EP1741445B1 (en) 2000-01-21 2013-08-14 Novartis AG Combinations comprising dipeptidylpeptidase-IV inhibitors and antidiabetic agents
JP2003520849A (ja) 2000-01-24 2003-07-08 ノボ ノルディスク アクティーゼルスカブ 酵素ｄｐｐ−ｉｖの阻害剤であるｎ−置換２−シアノピロールおよび−ピロリン
US6395767B2 (en) 2000-03-10 2002-05-28 Bristol-Myers Squibb Company Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method
US6608038B2 (en) 2000-03-15 2003-08-19 Novartis Ag Methods and compositions for treatment of diabetes and related conditions via gene therapy
WO2001072290A2 (en) 2000-03-31 2001-10-04 Probiodrug Ag Method for the improvement of islet signaling in diabetes mellitus and for its prevention
GB0010183D0 (en) 2000-04-26 2000-06-14 Ferring Bv Inhibitors of dipeptidyl peptidase IV
GB0010188D0 (en) 2000-04-26 2000-06-14 Ferring Bv Inhibitors of dipeptidyl peptidase IV
CN1440383A (zh) 2000-04-28 2003-09-03 三共株式会社 PPARγ调制剂
WO2001082916A2 (en) 2000-05-03 2001-11-08 Tularik Inc. Combination therapeutic compositions and methods of use
US6432969B1 (en) 2000-06-13 2002-08-13 Novartis Ag N-(substituted glycyl)-2 cyanopyrrolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV
TW583185B (en) 2000-06-13 2004-04-11 Novartis Ag N-(substituted glycyl)-2-cyanopyrrolidines and pharmaceutical composition for inhibiting dipeptidyl peptidase-IV (DPP-IV) or for the prevention or treatment of diseases or conditions associated with elevated levels of DPP-IV comprising the same
GB0014969D0 (en) 2000-06-19 2000-08-09 Smithkline Beecham Plc Novel method of treatment
US7078397B2 (en) 2000-06-19 2006-07-18 Smithkline Beecham Corporation Combinations of dipeptidyl peptidase IV inhibitors and other antidiabetic agents for the treatment of diabetes mellitus
US20030171399A1 (en) 2000-06-28 2003-09-11 Tularik Inc. Quinolinyl and benzothiazolyl modulators
EP1296967B1 (en) 2000-06-28 2006-05-31 Amgen Inc. Benzothiazolyl ppar-gamma modulators
EP1301187B1 (en) 2000-07-04 2005-07-06 Novo Nordisk A/S Purine-2,6-diones which are inhibitors of the enzyme dipeptidyl peptidase iv (dpp-iv)
DE60140708D1 (de) 2000-08-10 2010-01-14 Mitsubishi Tanabe Pharma Corp Prolinderivative und deren Verwendung als Medikamente
JP2004035574A (ja) 2000-10-06 2004-02-05 Tanabe Seiyaku Co Ltd 脂肪族含窒素五員環化合物
PT1325910E (pt) 2000-10-06 2008-10-27 Mitsubishi Tanabe Pharma Corp Compostos de anel alifático de cinco membros contendo azoto
JP4329291B2 (ja) 2000-10-06 2009-09-09 田辺三菱製薬株式会社 含窒素五員環化合物
JP4329290B2 (ja) 2000-10-06 2009-09-09 田辺三菱製薬株式会社 脂肪族含窒素五員環化合物
AUPR107800A0 (en) 2000-10-27 2000-11-23 University Of Sydney, The Peptide and nucleic acid molecule ii
TWI243162B (en) 2000-11-10 2005-11-11 Taisho Pharmaceutical Co Ltd Cyanopyrrolidine derivatives
CA2433090A1 (en) 2000-12-27 2002-07-04 Kyowa Hakko Kogyo Co., Ltd. Dipeptidyl peptidase iv inhibitor
WO2002053170A2 (de) 2001-01-02 2002-07-11 Institut Für Medizintechnologie Magdeburg Gmbh (Imtm) Kombinierte verwendung von enzyminhibitoren und pharmazeutischen zubereitungen daraus zur therapie und prophylaxe der arteriosklerose, zur therapie und prävention allergischer reaktionen von typ i nach gell und coombs und zur therapie und prävention dermatologischer erkrankungen mit follikulären und epidermalen hyperkeratos
DE10100053A1 (de) 2001-01-02 2002-08-22 Keyneurotek Ag I G Verwendung von Enzyminhibitoren der Dipeptidylpeptidase IV sowie der Aminopeptidase N und pharmazeutischen Zubereitungen daraus zur Prävention und/oder Therapie Ischämie-bedingter akuter und chronischer neurodegenerativer Prozesse und Erkrankungen
WO2002055088A1 (en) 2001-01-16 2002-07-18 Nippon Kayaku Kabushiki Kaisha Remedies for bone marrow suppression and infectious diseases and white blood cell count elevating agents
KR20030074774A (ko) 2001-02-02 2003-09-19 다케다 야쿠힌 고교 가부시키가이샤 접합 헤테로시클릭 화합물
JP4213390B2 (ja) 2001-02-02 2009-01-21 武田薬品工業株式会社 縮合複素環化合物
EA007485B1 (ru) 2001-02-24 2006-10-27 Берингер Ингельхайм Фарма Гмбх Унд Ко. Кг Производные ксантина, способ их получения, фармацевтическая композиция на их основе и способ ее получения
JP2002265439A (ja) 2001-03-08 2002-09-18 Mitsubishi Pharma Corp シアノピロリジン誘導体およびその医薬用途
ATE395912T1 (de) 2001-03-27 2008-06-15 Merck & Co Inc Dipeptidylpeptidase-hemmer für die behandlung oder prävention von diabetes
FR2822826B1 (fr) 2001-03-28 2003-05-09 Servier Lab Nouveaux derives sulfonyles d'alpha-amino-acides, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US6890905B2 (en) 2001-04-02 2005-05-10 Prosidion Limited Methods for improving islet signaling in diabetes mellitus and for its prevention
GB0109146D0 (en) 2001-04-11 2001-05-30 Ferring Bv Treatment of type 2 diabetes
US6573287B2 (en) 2001-04-12 2003-06-03 Bristo-Myers Squibb Company 2,1-oxazoline and 1,2-pyrazoline-based inhibitors of dipeptidyl peptidase IV and method
FR2824825B1 (fr) 2001-05-15 2005-05-06 Servier Lab Nouveaux derives d'alpha-amino-acides, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US20030060494A1 (en) 2001-05-18 2003-03-27 Nobuyuki Yasuda Pharmaceutical use of N-carbamoylazole derivatives
CA2450475A1 (en) 2001-06-20 2003-01-03 Linda Brockunier Dipeptidyl peptidase inhibitors for the treatment of diabetes
JP2004535433A (ja) 2001-06-20 2004-11-25 メルク　エンド　カムパニー　インコーポレーテッド 糖尿病治療用のジペプチジルペプチダーゼ阻害薬
GB0115517D0 (en) 2001-06-25 2001-08-15 Ferring Bv Novel antidiabetic agents
CN1990469A (zh) 2001-06-27 2007-07-04 史密丝克莱恩比彻姆公司 作为二肽酶抑制剂的氟代吡咯烷
DE60221983T2 (de) 2001-06-27 2008-05-15 Smithkline Beecham Corp. Fluorpyrrolidine als dipeptidyl-peptidase inhibitoren
DE10154689A1 (de) 2001-11-09 2003-05-22 Probiodrug Ag Substituierte Aminoketonverbindungen
US7368421B2 (en) 2001-06-27 2008-05-06 Probiodrug Ag Use of dipeptidyl peptidase IV inhibitors in the treatment of multiple sclerosis
EP1399471B1 (en) 2001-06-27 2008-01-30 Probiodrug AG Use of dipeptidyl peptidase iv inhibitors as therapeutics for neurological disorders
CN1688599A (zh) 2001-06-27 2005-10-26 前体生物药物股份有限公司 二肽基肽酶iv抑制剂的新用途
US20030130199A1 (en) 2001-06-27 2003-07-10 Von Hoersten Stephan Dipeptidyl peptidase IV inhibitors and their uses as anti-cancer agents
ES2296962T3 (es) 2001-06-27 2008-05-01 Smithkline Beecham Corporation Pirrolidinas como inhibidores de dipeptidil peptidasa.
US6869947B2 (en) 2001-07-03 2005-03-22 Novo Nordisk A/S Heterocyclic compounds that are inhibitors of the enzyme DPP-IV
EP1404675B1 (en) 2001-07-03 2008-03-12 Novo Nordisk A/S Dpp-iv-inhibiting purine derivatives for the treatment of diabetes
UA74912C2 (en) 2001-07-06 2006-02-15 Merck & Co Inc Beta-aminotetrahydroimidazo-(1,2-a)-pyrazines and tetratriazolo-(4,3-a)-pyrazines as inhibitors of dipeptylpeptidase for the treatment or prevention of diabetes
SG120880A1 (en) 2001-08-31 2006-04-26 Semiconductor Energy Lab Laser irradiation method, laser irradiation apparatus, and method of manufacturing a semiconductor device
DE10143840A1 (de) 2001-09-06 2003-03-27 Probiodrug Ag Neue Inhibitoren der Dipeptidylpeptidase I
US6844316B2 (en) 2001-09-06 2005-01-18 Probiodrug Ag Inhibitors of dipeptidyl peptidase I
EP1426366A4 (en) 2001-09-14 2004-12-08 Mitsubishi Pharma Corp THIAZOLIDE DERIVATIVES AND THEIR MEDICAL USE
AU2002331311A1 (en) 2001-09-19 2003-04-01 Novo Nordisk A/S Heterocyclic compounds that are inhibitors of the enzyme dpp-iv
GB0125445D0 (en) 2001-10-23 2001-12-12 Ferring Bv Protease Inhibitors
GB0125446D0 (en) 2001-10-23 2001-12-12 Ferring Bv Novel anti-diabetic agents
US6861440B2 (en) 2001-10-26 2005-03-01 Hoffmann-La Roche Inc. DPP IV inhibitors
JP2005507261A (ja) 2001-10-31 2005-03-17 ノバルティス アクチエンゲゼルシャフト Ｔｃｆ１遺伝子における多型に基づく糖尿病および関連状態の治療方法
US20030125304A1 (en) 2001-11-09 2003-07-03 Hans-Ulrich Demuth Substituted amino ketone compounds
US7236683B2 (en) 2001-11-15 2007-06-26 Macrovision Corporation Method and apparatus for providing or enhancing copy protection by adding selected negative-going and positive-going pulses in a video signal HBI
JP2005511636A (ja) 2001-11-26 2005-04-28 トラスティーズ オブ タフツ カレッジ 自己免疫疾患の治療方法及びそれに関する試薬
CA2468192A1 (en) 2001-11-26 2003-06-05 Trustees Of Tufts College Peptidomimetic inhibitors of post-proline cleaving enzymes
WO2003057144A2 (en) 2001-12-26 2003-07-17 Guilford Pharmaceuticals Change inhibitors of dipeptidyl peptidase iv
US6727261B2 (en) 2001-12-27 2004-04-27 Hoffman-La Roche Inc. Pyrido[2,1-A]Isoquinoline derivatives
US6725848B2 (en) 2002-01-18 2004-04-27 Detroit Diesel Corporation Method of controlling exhaust gas recirculation system based upon humidity
CA2475653A1 (en) 2002-02-08 2003-09-04 Idun Pharmaceuticals, Inc. (substituted)acyl dipeptidyl inhibitors of the ice/ced-3 family of cysteine proteases
DE60333166D1 (de) 2002-02-13 2010-08-12 Hoffmann La Roche Pyridin- und pyrimidin-derivate
CA2474460C (en) 2002-02-13 2009-12-22 F. Hoffmann-La Roche Ag Pyridine- and quinoline-derivatives
US6906074B2 (en) 2002-02-22 2005-06-14 Nippon Zoki Pharmaceutical Co., Ltd. 2-phenylpiperazine derivatives
JP2004043429A (ja) 2002-02-25 2004-02-12 Eisai Co Ltd 新規キサンチン誘導体およびｄｐｐｉｖ阻害剤
EP1338595B1 (en) 2002-02-25 2006-05-03 Eisai Co., Ltd. Xanthine derivatives as DPP-IV inhibitors
NZ534877A (en) 2002-02-28 2006-05-26 Prosidion Ltd Glutaminyl based DPIV inhibitors
HUP0200849A2 (hu) 2002-03-06 2004-08-30 Sanofi-Synthelabo N-aminoacetil-2-ciano-pirrolidin-származékok, e vegyületeket tartalmazó gyógyszerkészítmények és eljárás előállításukra
WO2003080633A1 (fr) 2002-03-25 2003-10-02 Nippon Kayaku Kabushiki Kaisha Nouveau derive d'$g(a)-amino-n-(diaminophosphinyl)lactame
US7307164B2 (en) 2002-03-25 2007-12-11 Merck & Co., Inc. β-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
JP4329381B2 (ja) 2002-04-04 2009-09-09 田辺三菱製薬株式会社 医薬組成物
JP4329382B2 (ja) 2002-04-04 2009-09-09 田辺三菱製薬株式会社 医薬組成物
US20040106802A1 (en) 2002-04-08 2004-06-03 Torrent Pharmaceuticals Ltd. Novel compounds and therapeutic uses thereof
CA2481995A1 (en) 2002-04-08 2003-10-16 Torrent Pharmaceuticals Ltd. Thiazolidine-4-carbonitriles and analogues and their use as dipeptidyl-peptidas inhibitors
JP2003300977A (ja) 2002-04-10 2003-10-21 Sumitomo Pharmaceut Co Ltd キサンチン誘導体
JPWO2003095425A1 (ja) 2002-05-09 2005-09-15 大正製薬株式会社 シアノピロリジン誘導体
JP2004026820A (ja) 2002-05-09 2004-01-29 Taisho Pharmaceut Co Ltd ジペプチジルペプチダーゼｉｖ阻害剤
JP2003327532A (ja) 2002-05-10 2003-11-19 Takeda Chem Ind Ltd ペプチダーゼ阻害剤
GB0212412D0 (en) 2002-05-29 2002-07-10 Novartis Ag Combination of organic compounds
SG154333A1 (en) 2002-06-03 2009-08-28 Novartis Ag The use of substituted cyanopyrrolidines and combination preparations containing them for treating hyperlipidemia and associated diseases
AU2003232405A1 (en) 2002-06-04 2003-12-19 Pfizer Products Inc. Flourinated cyclic amides as dipeptidyl peptidase iv inhibitors
AU2003233010A1 (en) 2002-06-04 2003-12-19 Pfizer Products Inc. Process for the preparation of 3,3,4,4-tetrafluoropyrrolidine and derivatives thereof
US6710040B1 (en) 2002-06-04 2004-03-23 Pfizer Inc. Fluorinated cyclic amides as dipeptidyl peptidase IV inhibitors
AU2003241960B2 (en) 2002-06-06 2009-07-30 Eisai R&D Management Co., Ltd. Novel fused imidazole derivative
HUP0202001A2 (hu) 2002-06-14 2005-08-29 Sanofi-Aventis DDP-IV gátló hatású azabiciklooktán- és nonánszármazékok
JP2004026678A (ja) 2002-06-24 2004-01-29 Microbial Chem Res Found ２型糖尿病治療剤
EP1578362A4 (en) 2002-07-09 2008-11-05 Point Therapeutics Inc COMBINATION THERAPY WITH A BOROPROLINE COMPOUND
AU2003248259A1 (en) 2002-07-10 2004-02-02 Yamanouchi Pharmaceutical Co., Ltd. Novel azetidine derivative or salt thereof
DE60330485D1 (de) 2002-07-15 2010-01-21 Merck & Co Inc Zur behandlung von diabetes
TW200401635A (en) 2002-07-23 2004-02-01 Yamanouchi Pharma Co Ltd 2-Cyano-4-fluoropyrrolidine derivative or salt thereof
AU2003253369A1 (en) 2002-07-29 2004-02-16 Tanabe Seiyaku Co., Ltd. Three-dimensional structure of dipeptidyl peptidase iv
JP4542757B2 (ja) 2002-08-08 2010-09-15 武田薬品工業株式会社 縮合複素環化合物
DE60322224D1 (de) 2002-08-08 2008-08-28 Takeda Pharmaceutical Kondensierte heterozyklische verbindungen als petidase inhibitoren
DE10238243A1 (de) 2002-08-21 2004-03-04 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-[3-Amino-piperidin-1-yl]-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
MEP59708A (en) 2002-08-21 2011-05-10 Boehringer Ingelheim Pharma 8-[3-amino-piperidin-1-yl]-xanthines, the production thereof and the use of the same as medicaments
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
DE10238477A1 (de) 2002-08-22 2004-03-04 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Purinderivate, deren Herstellung und deren Verwendung als Arzneimittel
DE10238470A1 (de) 2002-08-22 2004-03-04 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Xanthinderivate, deren Herstellung und deren Verwendung als Arzneimittel
US7064643B2 (en) 2002-08-26 2006-06-20 Matsushita Electric Industrial Co., Ltd. Multi-phasemagnetic element and production method therefor
US7304166B2 (en) 2002-08-29 2007-12-04 Taisho Pharmaceutical Co., Ltd. Benzenesulfonate salt of 4-fluoro-2-cyanopyrrolidine derivatives
US8895541B2 (en) 2002-09-04 2014-11-25 James A. Carnazza Methods for inhibiting the development of huntington's disease
US20060039974A1 (en) 2002-09-11 2006-02-23 Takeda Pharmaceutical Company Limited Sustained release preparation
US7238724B2 (en) 2002-09-19 2007-07-03 Abbott Laboratories Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV)
US20040121964A1 (en) 2002-09-19 2004-06-24 Madar David J. Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV)
US7262207B2 (en) 2002-09-19 2007-08-28 Abbott Laboratories Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV)
EP1554280B1 (en) 2002-10-07 2007-08-15 Merck & Co., Inc. Antidiabetic beta-amino heterocyclic dipeptidyl peptidase inhibitors
WO2004033455A2 (en) 2002-10-08 2004-04-22 Novo Nordisk A/S Hemisuccinate salts of heterocyclic dpp-iv inhibitors
PL216527B1 (pl) 2002-10-18 2014-04-30 Merck & Co Inc Związki ß-aminoheterocykliczne i kompozycja farmaceutyczna
ATE469645T1 (de) 2002-10-23 2010-06-15 Bristol Myers Squibb Co Auf glycinnitril basierende hemmer der dipeptidylpeptidase iv
WO2004041795A1 (en) 2002-10-30 2004-05-21 Guilford Pharmaceuticals Inc. Novel inhibitors of dipeptidyl peptidase iv
AU2003280680A1 (en) 2002-11-01 2004-06-18 Sumitomo Pharmaceuticals Co., Ltd. Xanthine compound
EP1562925B1 (en) 2002-11-07 2007-01-03 Merck & Co., Inc. Phenylalanine derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
US7482337B2 (en) 2002-11-08 2009-01-27 Boehringer Ingelheim Pharma Gmbh & Co. Kg Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions
DE10251927A1 (de) 2002-11-08 2004-05-19 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Xanthinderivate, deren Herstellung und deren Verwendung als Arzneimittel
BR0316327A (pt) 2002-11-18 2005-09-27 Pfizer Prod Inc Amidas cìclicas fluorinadas inibidoras de dipeptidilpeptidase iv
DE10254304A1 (de) 2002-11-21 2004-06-03 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Xanthinderivate, deren Herstellung und deren Verwendung als Arzneimittel
DE10256264A1 (de) 2002-12-03 2004-06-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue substituierte Imidazo-pyridinone und Imidazo-pyridazinone, ihre Herstellung und ihre Verwendung als Arzneimittel
UY28103A1 (es) 2002-12-03 2004-06-30 Boehringer Ingelheim Pharma Nuevas imidazo-piridinonas sustituidas, su preparación y su empleo como medicacmentos
US7109192B2 (en) 2002-12-03 2006-09-19 Boehringer Ingelheim Pharma Gmbh & Co Kg Substituted imidazo-pyridinones and imidazo-pyridazinones, the preparation thereof and their use as pharmaceutical compositions
CA2508487A1 (en) 2002-12-04 2004-06-17 Merck & Co., Inc. Phenylalanine derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
US7420079B2 (en) 2002-12-09 2008-09-02 Bristol-Myers Squibb Company Methods and compounds for producing dipeptidyl peptidase IV inhibitors and intermediates thereof
DE60322944D1 (de) 2002-12-10 2008-09-25 Novartis Ag Kombinationen von einem dpp-iv inhibitor und einem ppar- alpha agonist
EP1583534A4 (en) 2002-12-20 2007-08-29 Merck & Co Inc 3-AMINO-4-PHENYLBUTANIC ACID DERIVATIVES AS DIPEPTIDYL-PEPTIDASE INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES
CA2512546A1 (en) 2003-01-17 2004-08-05 Merck & Co., Inc. 3-amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
JP2004244412A (ja) 2003-01-20 2004-09-02 Kotobuki Seiyaku Kk ４位に置換基を有する２−シアノピロリジン誘導体及びその製造方法並びにそれを含有する薬剤
JP4345313B2 (ja) 2003-01-24 2009-10-14 株式会社日立製作所 ポリシーに基づいたストレージシステムの運用管理方法
CA2513684A1 (en) 2003-01-31 2004-08-19 Merck & Co., Inc. 3-amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
EP1595866B1 (en) 2003-01-31 2016-06-08 Sanwa Kagaku Kenkyusho Co., Ltd. Cyanopyrrolidines useful for the treatment of inter alia metabolic syndrome
WO2004071454A2 (en) 2003-02-13 2004-08-26 Guilford Pharmaceuticals Inc. Substituted azetidine compounds as inhibitors of dipeptidyl peptidase iv
WO2004076434A1 (en) 2003-02-28 2004-09-10 Aic Dipeptidyl peptidase inhibitors
WO2004076433A1 (en) 2003-02-28 2004-09-10 Aic Dipeptidyl peptidase inhibitors
AR043515A1 (es) 2003-03-19 2005-08-03 Merck & Co Inc Procedimiento para preparar derivados quirales beta aminoacidos mediante hidrogenacion asimetrica
WO2004085661A2 (en) 2003-03-24 2004-10-07 Merck & Co., Inc Process to chiral beta-amino acid derivatives
US20040242568A1 (en) 2003-03-25 2004-12-02 Syrrx, Inc. Dipeptidyl peptidase inhibitors
WO2004087650A2 (en) 2003-03-27 2004-10-14 Merck & Co. Inc. Process and intermediates for the preparation of beta-amino acid amide dipeptidyl peptidase-iv inhibitors
WO2004092128A1 (en) 2003-04-10 2004-10-28 Smithkline Beecham Corporation Anhydrous crystalline forms of (2s, 4s)-1-{(2r)-2-amino-3-‘4-methoxybenzyl)sulfonyl!-3-methylbutanoyl}-4-fluoropyrrolindine-2-carbonitrile
JPWO2004096806A1 (ja) 2003-04-30 2006-07-13 大日本住友製薬株式会社 縮合イミダゾール誘導体
WO2004099134A2 (en) 2003-05-05 2004-11-18 Prosidion Ltd. Glutaminyl based dp iv-inhibitors
US20040224995A1 (en) 2003-05-09 2004-11-11 University Of North Texas Health Science Center At Fort Worth Neuroprotective effects of PPARy agonists against cellular oxidative insults
WO2004103993A1 (en) 2003-05-14 2004-12-02 Syrrx, Inc. Dipeptidyl peptidase inhibitors
CN1787823A (zh) 2003-05-14 2006-06-14 麦克公司 作为二肽基肽酶抑制剂用于治疗或预防糖尿病的3－氨基－4－苯基丁酸衍生物
EP1627870A1 (en) 2003-05-15 2006-02-22 Taisho Pharmaceutical Co., Ltd Cyanofluoropyrrolidine derivative
WO2004104215A2 (en) 2003-05-21 2004-12-02 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with dipeptidylpeptidase 7 (dpp7)
WO2004104216A2 (en) 2003-05-21 2004-12-02 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with dipeptidylpeptidase iv (dpp4)
AU2003902828A0 (en) 2003-06-05 2003-06-26 Fujisawa Pharmaceutical Co., Ltd. Dpp-iv inhibitor
CN1798556A (zh) 2003-06-06 2006-07-05 麦克公司 作为治疗或者预防糖尿病的二肽基肽酶抑制剂的稠合吲哚
US20070099884A1 (en) 2003-06-06 2007-05-03 Erondu Ngozi E Combination therapy for the treatment of diabetes
AU2003902946A0 (en) 2003-06-12 2003-06-26 Fujisawa Pharmaceutical Co., Ltd. Dpp-iv inhibitor
WO2004112701A2 (en) 2003-06-17 2004-12-29 Merck & Co., Inc. Cyclohexylglycine derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
DE10327439A1 (de) 2003-06-18 2005-01-05 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Imidazopyridazinon- und Imidazopyridonderivate, deren Herstellung und deren Verwendung als Arzneimittel
US7566707B2 (en) 2003-06-18 2009-07-28 Boehringer Ingelheim International Gmbh Imidazopyridazinone and imidazopyridone derivatives, the preparation thereof and their use as pharmaceutical compositions
HRP20110018T1 (hr) 2003-06-20 2011-02-28 F. Hoffmann - La Roche Ag Derivati pirido(2,1-a)-izokinolina kao inhibitori dpp-iv
AU2004251829B2 (en) 2003-06-20 2009-12-17 F. Hoffmann-La Roche Ag Hexahydropyridoisoqinolines as DPP-IV inhibitors
JO2625B1 (en) 2003-06-24 2011-11-01 ميرك شارب اند دوم كوربوريشن Phosphoric acid salts of dipeptidyl betidase inhibitor 4
JP2005023038A (ja) 2003-07-04 2005-01-27 Taisho Pharmaceut Co Ltd 慢性腎疾患治療薬
WO2005009956A1 (en) 2003-07-21 2005-02-03 Smithkline Beecham Corporation (2s,4s)-4-fluoro-1-[4-fluoro-beta-(4-fluorophenyl)-l-phenylalanyl]-2-pyrrolidinecarbonitrile p-toluenesulfonic acid salt and anhydrous crystalline forms thereof
PE20050249A1 (es) 2003-07-25 2005-06-01 Aventis Pharma Gmbh Nuevas cianopirrolididas y procedimiento para su preparacion como medicamentos
US7008957B2 (en) 2003-07-25 2006-03-07 Sanofi-Aventis Deutschland Gmbh Bicyclic cyanoheterocycles, process for their preparation and their use as medicaments
US7094800B2 (en) 2003-07-25 2006-08-22 Sanofi-Aventis Deutschland Gmbh Cyanopyrrolidides, process for their preparation and their use as medicaments
DE10333935A1 (de) 2003-07-25 2005-02-24 Aventis Pharma Deutschland Gmbh Neue bicyclische Cyanoheterocyclen, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
CA2533893A1 (en) 2003-07-31 2005-02-10 Merck & Co., Inc. Hexahydrodiazepinones as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
US20050065183A1 (en) 2003-07-31 2005-03-24 Indranil Nandi Fexofenadine composition and process for preparing
US6995183B2 (en) 2003-08-01 2006-02-07 Bristol Myers Squibb Company Adamantylglycine-based inhibitors of dipeptidyl peptidase IV and methods
DE10337074A1 (de) 2003-08-12 2005-03-17 Keyneurotek Ag Verwendung der Inhibitoren von Enzymen mit Aktivitäten der Aminopeptidase N und/oder der Dipeptidylpeptidase IV und pharmazeutischen Zubereitungen daraus zur Therapie und Prävention von chronischen neurodegenerativen Erkrankungen
EP1506967B1 (en) 2003-08-13 2007-11-21 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
US7169926B1 (en) 2003-08-13 2007-01-30 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
WO2005019168A2 (en) 2003-08-20 2005-03-03 Pfizer Products Inc. Fluorinated lysine derivatives as dipeptidyl peptidase iv inhibitors
WO2005021550A1 (ja) 2003-08-29 2005-03-10 Dainippon Sumitomo Pharma Co., Ltd. 二環性ピラゾール誘導体
HU227684B1 (en) 2003-08-29 2011-11-28 Sanofi Aventis Adamantane and azabicyclo-octane and nonane derivatives and their use as dpp-iv inhibitors
CA2536251C (en) 2003-09-02 2009-08-04 Merck & Co., Inc. Novel crystalline forms of a phosphoric acid salt of a dipeptidyl peptidase-iv inhibitor
US7205409B2 (en) 2003-09-04 2007-04-17 Abbott Laboratories Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV)
WO2005023762A1 (en) 2003-09-04 2005-03-17 Abbott Laboratories Pyrrolidine-2-carbonitrile derivatives and their use as inhibitors of dipeptidyl peptidase-iv (dpp-iv)
JP2007513058A (ja) 2003-09-08 2007-05-24 武田薬品工業株式会社 ジペプチジルぺプチダーゼ阻害剤
EP1699777B1 (en) 2003-09-08 2012-12-12 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
TW200530157A (en) 2003-09-09 2005-09-16 Japan Tobacco Inc Dipeptidyl peptidase iv inhibitor
GB0321100D0 (en) 2003-09-09 2003-10-08 Celltech R&D Ltd Biological products
EP1667524A4 (en) 2003-09-23 2009-01-14 Merck & Co Inc NEW CRYSTALLINE FORM OF A PHOSPHORIC ACID SALT OF A DIPEPTIDYLPEPTIDASE IV INHIBITOR
EP1671649B1 (en) 2003-10-03 2011-11-23 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase IV inhibitors for treating diabetic patients with sulfonylurea secondary failure
WO2005033099A2 (en) 2003-10-03 2005-04-14 Glenmark Pharmaceuticals Ltd. Novel dipeptidyl peptidase iv inhibitors; processes for their preparation and compositions thereof
US7223761B2 (en) 2003-10-03 2007-05-29 Amgen Inc. Salts and polymorphs of a potent antidiabetic compound
DE10348044A1 (de) 2003-10-15 2005-05-19 Imtm Gmbh Duale Alanyl-Aminopeptidase- und Dipeptidylpeptidase IV-Inhibitoren zur funktionellen Beeinflussung unterschiedlicher Zellen und zur Behandlung immunologischer, entzündlicher, neuronaler und anderer Erkrankungen
DE10348022A1 (de) 2003-10-15 2005-05-25 Imtm Gmbh Neue Dipeptidylpeptidase IV-Inhibitoren zur funktionellen Beeinflussung unterschiedlicher Zellen und zur Behandlung immunologischer, entzündlicher, neuronaler und anderer Erkrankungen
GB0324236D0 (en) 2003-10-16 2003-11-19 Astrazeneca Ab Chemical compounds
TW200519105A (en) 2003-10-20 2005-06-16 Lg Life Science Ltd Novel inhibitors of DPP-IV, methods of preparing the same, and pharmaceutical compositions containing the same as an active agent
EP1684786A4 (en) 2003-10-24 2007-12-12 Merck & Co Inc IMPROVING THE MIRROR OF THE GROWTH HORMONE WITH A DIPEPTIDYL PEPTIDASE IV INHIBITOR AND A GROWTH HORMONE SECRETAGOG
TW200528440A (en) 2003-10-31 2005-09-01 Fujisawa Pharmaceutical Co 2-cyanopyrrolidinecarboxamide compound
TW200523252A (en) 2003-10-31 2005-07-16 Takeda Pharmaceutical Pyridine compounds
CN1874774B (zh) 2003-10-31 2011-04-13 武田药品工业株式会社 包含胰岛素致敏剂、胰岛素促分泌素和聚氧乙烯脱水山梨醇脂肪酸酯的固体制剂
JP2007510651A (ja) 2003-11-04 2007-04-26 メルク　エンド　カムパニー　インコーポレーテッド 糖尿病の治療又は予防のためのジペプチジルペプチダーゼ−ｉｖ阻害剤としての縮合フェニルアラニン誘導体
US7767828B2 (en) 2003-11-12 2010-08-03 Phenomix Corporation Methyl and ethyl substituted pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV
US7317109B2 (en) 2003-11-12 2008-01-08 Phenomix Corporation Pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV
US7674913B2 (en) 2003-11-12 2010-03-09 Phenomix Corporation Heterocyclic boronic acid compounds
CA2545641A1 (en) 2003-11-17 2005-06-02 Novartis Ag Use of organic compounds
US20070149451A1 (en) 2003-11-17 2007-06-28 Holmes David G Combination of a dpp IV inhibitor and an antiobesity or appetite regulating agent
JPWO2005051949A1 (ja) 2003-11-26 2007-06-21 住友製薬株式会社 新規縮合イミダゾール誘導体
DE10355304A1 (de) 2003-11-27 2005-06-23 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue 8-(Piperazin-1-yl)-und 8-([1,4]Diazepan-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
US7504423B2 (en) 2003-12-11 2009-03-17 Mitsubishi Tanabe Pharma Corporation α-amino acid derivatives and use thereof as medicines
WO2005058849A1 (en) 2003-12-15 2005-06-30 Glenmark Pharmaceuticals Ltd. New dipeptidyl peptidase in inhibitors; process for their preparation and compositions containing them
US7217711B2 (en) 2003-12-17 2007-05-15 Boehringer Ingelheim International Gmbh Piperazin-1-yl and 2-([1,4]diazepan-1-yl)-imidazo[4,5-d]-pyridazin-4-ones, the preparation thereof and their use as pharmaceutical compositions
DE10360835A1 (de) 2003-12-23 2005-07-21 Boehringer Ingelheim Pharma Gmbh & Co. Kg Bicyclische Imidazolverbindungen, deren Herstellung und deren Verwendung als Arzneimittel
EP1708571A4 (en) 2004-01-16 2009-07-08 Merck & Co Inc NEW CRYSTALLINE SALTS OF A DIPEPTIDYLPEPTIDASE IV HEMMER
EP1559419A1 (en) 2004-01-23 2005-08-03 Fournier Laboratories Ireland Limited Pharmaceutical formulations comprising metformin and a fibrate, and processes for their obtention
KR20050076924A (ko) 2004-01-26 2005-07-29 삼성전자주식회사 양방향 통신이 가능한 ｉ2ｃ 통신시스템 및 그 방법
US7230002B2 (en) 2004-02-03 2007-06-12 Glenmark Pharmaceuticals Ltd. Dipeptidyl peptidase IV inhibitors; processes for their preparation and compositions thereof
WO2005075426A1 (en) 2004-02-03 2005-08-18 Glenmark Pharmaceuticals Ltd. Novel dipeptidyl peptidase iv inhibitors; processes for their preparation and compositions thereof
US7501426B2 (en) 2004-02-18 2009-03-10 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
WO2005079795A2 (en) 2004-02-20 2005-09-01 Novartis Ag Dpp-iv inhibitors for treating neurodegeneration and cognitive disorders
DE102004009039A1 (de) 2004-02-23 2005-09-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-[3-Amino-piperidin-1-yl]-xanthine, deren Herstellung und Verwendung als Arzneimittel
AU2005217642B2 (en) 2004-02-23 2012-04-12 Trustees Of Tufts College Lactams as conformationally constrained peptidomimetic inhibitors
MXPA06009589A (es) 2004-02-23 2007-03-26 Tufts College Inhibidores de dipeptidil peptidasa iv par regular el metabolismo de glucosa.
US20050215603A1 (en) 2004-03-08 2005-09-29 Irini Akritopoulou-Zanze Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV)
AU2005221140A1 (en) 2004-03-08 2005-09-22 Amgen Inc. Therapeutic modulation of PPAR (gamma) activity
US7348346B2 (en) 2004-03-08 2008-03-25 Abbott Laboratories Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV)
US20070093492A1 (en) 2004-03-09 2007-04-26 Weir-Torn Jiaang Pyrrolidine derivatives
CN1942186B (zh) 2004-03-09 2010-10-06 国家卫生研究院 吡咯烷化合物
US7393847B2 (en) 2004-03-13 2008-07-01 Boehringer Ingleheim International Gmbh Imidazopyridazinediones, their preparation and their use as pharmaceutical compositions
MXPA06010571A (es) 2004-03-15 2007-02-16 Takeda Pharmaceutical Inhibidores de dipeptidil peptidasa.
CA2557801C (en) 2004-03-16 2013-06-25 Boehringer Ingelheim International Gmbh Glucopyranosyl-substituted benzol derivatives, drugs containing said compounds, the use thereof and method for the production thereof
US20050215882A1 (en) 2004-03-23 2005-09-29 The Regents Of The University Of Michigan Noninvasive method to determine fat content of tissues using MRI
TW200538122A (en) 2004-03-31 2005-12-01 Bristol Myers Squibb Co Process for preparing a dipeptidyl peptidase Ⅳ inhibitor and intermediates employed therein
US7179809B2 (en) 2004-04-10 2007-02-20 Boehringer Ingelheim International Gmbh 2-Amino-imidazo[4,5-d]pyridazin-4-ones, their preparation and their use as pharmaceutical compositions
EP1738754B1 (en) 2004-04-14 2015-07-15 Takeda Pharmaceutical Company Limited Solid pharmaceutical preparation
US7741082B2 (en) 2004-04-14 2010-06-22 Bristol-Myers Squibb Company Process for preparing dipeptidyl peptidase IV inhibitors and intermediates therefor
TW200536827A (en) 2004-05-04 2005-11-16 Bristol Myers Squibb Co Enzymatic ammonolysis process for the preparation of intermediates for DPP IV inhibitors
JP2007538079A (ja) 2004-05-18 2007-12-27 メルク　エンド　カムパニー　インコーポレーテッド 糖尿病の治療又は予防のためのジペプチジルペプチダーゼ−ｉｖ阻害剤としてのシクロヘキシルアラニン誘導体
US7687638B2 (en) 2004-06-04 2010-03-30 Takeda San Diego, Inc. Dipeptidyl peptidase inhibitors
DE102004030502A1 (de) 2004-06-24 2006-01-12 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Imidazole und Triazole, deren Herstellung und Verwendung als Arzneimittel
WO2006019965A2 (en) 2004-07-16 2006-02-23 Takeda San Diego, Inc. Dipeptidyl peptidase inhibitors
JP5010918B2 (ja) 2004-07-21 2012-08-29 キッセイ薬品工業株式会社 肝臓脂肪の異常蓄積に起因する疾患の進展抑制剤
US7165453B2 (en) 2004-07-23 2007-01-23 Electric Power Research Institute Flexible electromagnetic acoustic transducer sensor
US7054436B2 (en) 2004-08-02 2006-05-30 Sony Ericsson Mobile Communication, Ab Communication terminals with a dual use speaker for sensing background noise and generating sound, and related methods and computer program products
US20060046978A1 (en) 2004-08-31 2006-03-02 Morphochem Ag Novel compounds that inhibit dipeptidyl peptidase (DPP-IV) and neprilysin (NEP) and/or angiotensin converting enzyme (ACE)
DE102004043944A1 (de) 2004-09-11 2006-03-30 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue 8-(3-Amino-piperidin-1-yl)-7-(but-2-inyl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
DE102004044221A1 (de) 2004-09-14 2006-03-16 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue 3-Methyl-7-butinyl-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
WO2006034435A2 (en) 2004-09-21 2006-03-30 Point Therapeutics, Inc. Methods and compositions for treating glucose-associated conditions, metabolic syndrome, dyslipidemias and other conditions
AR051446A1 (es) 2004-09-23 2007-01-17 Bristol Myers Squibb Co Glucosidos de c-arilo como inhibidores selectivos de transportadores de glucosa (sglt2)
AP2007003973A0 (en) 2004-10-12 2007-07-30 Glenmark Pharmaceuticals Sa Novel dideptidyl peptidase IV inhibitors, pharmaceutical compositions containing them, and proces for their preparation
EP1812378A2 (en) 2004-10-13 2007-08-01 University of Connecticut Cannabinergic lipid ligands
US20060252670A1 (en) 2004-10-14 2006-11-09 Intercept Pharmaceuticals Inc. Method of reducing drug-induced adverse side effects in a patient
EP1656934A1 (en) * 2004-11-12 2006-05-17 Cognis IP Management GmbH Use of physiologically active fatty acids for treating lipodystrophy
CA2587524A1 (en) 2004-11-30 2006-06-08 F. Hoffmann-La Roche Ag Substituted benzoquinolizine derivates
TW200635599A (en) 2004-12-16 2006-10-16 Boehringer Ingelheim Int Glucopyranosyl-substituted benzene derivatives, medicaments containing such compounds, their use and process for their manufacture
US7411093B2 (en) 2004-12-20 2008-08-12 Hoffman-La Roche Inc. Aminocycloalkanes as DPP-IV inhibitors
MX2007007434A (es) 2004-12-20 2007-07-17 Hoffmann La Roche Derivados de 4-aminopiperidina.
EP1828192B1 (en) 2004-12-21 2014-12-03 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
DOP2006000008A (es) 2005-01-10 2006-08-31 Arena Pharm Inc Terapia combinada para el tratamiento de la diabetes y afecciones relacionadas y para el tratamiento de afecciones que mejoran mediante un incremento de la concentración sanguínea de glp-1
WO2006100181A2 (en) 2005-03-22 2006-09-28 F. Hoffmann-La Roche Ag New salt and polymorphs of a dpp-iv inhibitor
EP1888562B1 (en) 2005-04-22 2014-06-18 Alantos Pharmaceuticals Holding, Inc. Dipeptidyl peptidase-iv inhibitors
US7723309B2 (en) 2005-05-03 2010-05-25 Boehringer Ingelheim International Gmbh Crystalline forms of 1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-((R)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments
UA91546C2 (uk) 2005-05-03 2010-08-10 Бьорінгер Інгельхайм Інтернаціональ Гмбх КРИСТАЛІЧНА ФОРМА 1-ХЛОР-4-(β-D-ГЛЮКОПІРАНОЗ-1-ИЛ)-2-[4-((S)-ТЕТРАГІДРОФУРАН-3-ІЛОКСИ)-БЕНЗИЛ]-БЕНЗОЛУ, СПОСІБ ЇЇ ОДЕРЖАННЯ ТА ЇЇ ЗАСТОСУВАННЯ ПРИ ПРИГОТУВАННІ ЛІКАРСЬКИХ ЗАСОБІВ
US7644148B2 (en) 2005-05-16 2010-01-05 Hewlett-Packard Development Company, L.P. Historical data based workload allocation
US7521557B2 (en) 2005-05-20 2009-04-21 Bristol-Myers Squibb Company Pyrrolopyridine-based inhibitors of dipeptidyl peptidase IV and methods
US20060264433A1 (en) 2005-05-23 2006-11-23 Backes Bradley J Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV)
US7825139B2 (en) 2005-05-25 2010-11-02 Forest Laboratories Holdings Limited (BM) Compounds and methods for selective inhibition of dipeptidyl peptidase-IV
US20060270722A1 (en) 2005-05-31 2006-11-30 Thornberry Nancy A Combination of a dipeptidyl peptidase-IV inhibitor and a dual PPAR agonist for the treatment of diabetes and obesity
CN101272805A (zh) 2005-07-12 2008-09-24 第一三共株式会社 包含PPARγ激动剂的药物组合物
CA2617715A1 (en) 2005-08-11 2007-02-15 F. Hoffmann-La Roche Ag Pharmaceutical composition comprising a dpp-iv inhibitor
US7425633B2 (en) 2005-08-26 2008-09-16 National Health Research Institutes Pyrrolidine compounds
DE602006017566D1 (de) 2005-08-30 2010-11-25 Boehringer Ingelheim Pharma Glucopyranosyl-substituierte benzyl-derivate, medikamente mit solchen verbindungen, ihre verwendung und herstellungsverfahren dafür
WO2007027651A2 (en) 2005-08-30 2007-03-08 Abbott Laboratories Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-iv (dpp-iv)
ES2358051T3 (es) 2005-09-08 2011-05-05 Boehringer Ingelheim International Gmbh Formas cristalinas de 1-cloro-4-(beta-d-glucopiranos-1-il)-2-(4-etinil-bencil)-benceno, métodos para su preparación y su uso para preparar medicamentos.
AR056195A1 (es) 2005-09-15 2007-09-26 Boehringer Ingelheim Int Procedimientos para preparar derivados de (etinil-bencil)-benceno sustituidos de glucopiranosilo y compuestos intermedios de los mismos
AT502717A1 (de) 2005-11-09 2007-05-15 Omnica Gmbh Pharmazeutische verwendung einer verbindung
WO2007054577A1 (en) 2005-11-14 2007-05-18 Probiodrug Ag Cyclopropyl-fused pyrrolidine derivatives as dipeptidyl peptidase iv inhibitors
ES2351471T3 (es) 2005-12-21 2011-02-07 F. Hoffmann-La Roche Ag Nueva sal y polimorfo de inhibidores de dpp-iv.
ZA200805147B (en) 2005-12-22 2010-05-26 Takeda Pharmaceutical Solid preparation
AU2007216452A1 (en) 2006-02-15 2007-08-23 Boehringer Ingelheim International Gmbh Glucopyranosyl-substituted benzonitrile derivatives, pharmaceutical compositions containing such compounds, their use and process for their manufacture
US20070239536A1 (en) 2006-04-05 2007-10-11 General Electric Company System and method for scheduling audience deficiency units and makegoods
PE20080697A1 (es) 2006-05-03 2008-08-05 Boehringer Ingelheim Int Derivados de benzonitrilo sustituidos con glucopiranosilo, composiciones farmaceuticas que contienen compuestos de este tipo, su uso y procedimiento para su fabricacion
EP2032134B1 (en) * 2006-05-09 2015-06-24 Genzyme Corporation Methods of treating fatty liver disease comprising inhibiting glucosphingolipid synthesis
DE602007005139D1 (de) 2006-07-21 2010-04-15 Novartis Ag Formulierungen für benzimidazolylpyridylether
EP2086991A1 (en) 2006-10-27 2009-08-12 Boehringer Ingelheim International GmbH CRYSTALLINE FORM OF 4-(ß-D-GLUCOPYRANOS-1-YL)-1-METHYL-2-[4-((S)-TETRAHYDROFURAN-3-YLOXY)-BENZYL]-BENZENE, A METHOD FOR ITS PREPARATION AND THE USE THEREOF FOR PREPARING MEDICAMENTS
US7879806B2 (en) 2006-11-06 2011-02-01 Boehringer Ingelheim International Gmbh Glucopyranosyl-substituted benzyl-benzonitrile derivates, medicaments containing such compounds, their use and process for their manufacture
EA018495B1 (ru) 2006-11-09 2013-08-30 Бёрингер Ингельхайм Интернациональ Гмбх Комбинированное лечение ингибиторами sglt-2 (натрийзависимый сопереносчик глюкозы 2) и содержащими их фармацевтическими композициями
US20080132555A1 (en) 2006-11-28 2008-06-05 Auspex Pharmaceuticals, Inc. Preparation and utility of substituted phenyltetrazoles
US20070172525A1 (en) 2007-03-15 2007-07-26 Ramesh Sesha Anti-diabetic combinations
CA2721133C (en) 2007-04-13 2018-11-06 Somaxon Pharmaceuticals, Inc. Low-dose doxepin formulations and methods of making and using the same
AU2008273997A1 (en) 2007-07-11 2009-01-15 Cardoz Ab Combination for use in the treatment of atherosclerosis comprising a mast cell inhibitor and a PPAR gamma agonist
WO2009015179A1 (en) 2007-07-23 2009-01-29 Syndax Pharmaceuticals, Inc. Novel compounds and methods of using them
CN101361968B (zh) 2007-08-06 2011-08-03 健能隆医药技术（上海）有限公司 白介素-22在治疗脂肪肝中的应用
WO2009097996A1 (de) 2008-02-07 2009-08-13 Sanofi-Aventis Verwendung von substituierten phenylimidazolidinen zur herstellung von arzneimitteln zur behandlung des metabolischen syndroms
WO2009097997A1 (de) 2008-02-07 2009-08-13 Sanofi-Aventis Substituierte imidazolidin-2,4-dione, verfahren zu ihrer herstellung, diese verbindungen enthaltende arzneimittel und ihre verwendung
US20130245024A1 (en) 2008-03-06 2013-09-19 Dennis Lanfear Combination of PPARy Agonist and a Dipeptidyl Peptidase-Inhibitor for the Treatment of Diabetes and Obesity
WO2010040055A2 (en) 2008-10-03 2010-04-08 Intekrin Therapeutics, Inc. Oral pharmaceutical formulations for antidiabetic compounds
JP2010265216A (ja) 2009-05-14 2010-11-25 Takeda Chem Ind Ltd 複素環化合物
US9028879B2 (en) 2009-07-01 2015-05-12 Jds Therapeutics, Llc Chromium complexes as enhancers of brain glucose transporters
WO2011017488A2 (en) * 2009-08-05 2011-02-10 Intekrin Therapeutics, Inc. Combination of a selective ppar-gamma modulator and an incretin for the treatment of diabetes and obesity
US9675603B2 (en) 2010-09-21 2017-06-13 Intekrin Therapeutics, Inc. Solid pharmaceutical compositions of ppary modulator
US8477001B2 (en) 2010-09-21 2013-07-02 Remy Technologies Llc Starter solenoid with rectangular coil winding
US9267164B2 (en) 2010-09-26 2016-02-23 Da Yu Enterprises, L.L.C. Method of recombinant macromolecular production
US9072732B2 (en) 2010-11-22 2015-07-07 The Regents Of The University Of California Indication for use of niacin (nicotinic acid) for treatment and reversal of fatty liver disease
TWI435605B (zh) 2010-11-29 2014-04-21 Realtek Semiconductor Corp 透過高解析度多媒體介面來進行網路連線之網路裝置及網路連線方法
ES2389547B1 (es) 2010-12-07 2013-08-08 Consejo Superior De Investigaciones Científicas (Csic) Bifidobacterium cect 7765 y su uso en la prevención y/o tratamiento del sobrepeso, la obesidad y patologías asociadas.
US8865641B2 (en) 2011-06-16 2014-10-21 The Feinstein Institute For Medical Research Methods of treatment of fatty liver disease by pharmacological activation of cholinergic pathways
US9044433B2 (en) 2011-10-06 2015-06-02 Vanderbilt University Compositions and methods for treating and preventing hyperlipidemia, fatty liver, atherosclerosis and other disorders associated with metabolic syndrome
WO2013071077A1 (en) 2011-11-09 2013-05-16 Cornell University The use of pan-ppar agonists for prevention and treatment of huntington's disease and tauopathies
KR101186500B1 (ko) 2012-01-31 2012-09-27 연세대학교 산학협력단 신규한 피페린 유도체 및 그의 용도
US9499472B2 (en) 2012-03-05 2016-11-22 The University Of Montana Aspartylamide inhibitors of excitatory amino acid transporters
PE20151435A1 (es) 2012-10-12 2015-10-15 Teva Pharma Laquinimod para reducir el dano talamico en la esclerosis multiple
WO2014120538A1 (en) 2013-01-30 2014-08-07 Intekrin Therapeutics, Inc. PPARγ AGONISTS FOR TREATMENT OF MULTIPLE SCLEROSIS
US10441560B2 (en) 2013-03-15 2019-10-15 Mochida Pharmaceutical Co., Ltd. Compositions and methods for treating non-alcoholic steatohepatitis
US9612248B2 (en) 2013-03-15 2017-04-04 Somalogic, Inc. Nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) biomarkers and uses thereof
EP3082814A4 (en) 2013-12-20 2017-06-21 Teva Pharmaceutical Industries Ltd. Use of laquinimod to delay huntington's disease progression
JP2017506651A (ja) 2014-02-27 2017-03-09 ニューサート サイエンシーズ， インコーポレイテッド 脂肪肝の低減または予防のための組成物および方法
CA2963354A1 (en) 2014-10-10 2016-04-14 Prometic Biosciences Inc. Substituted aromatic compounds and pharmaceutical compositions for the prevention and treatment of osteoporosis
CN104299589B (zh) 2014-10-29 2016-05-25 京东方科技集团股份有限公司 移位寄存器单元电路、移位寄存器、驱动方法及显示装置
KR20160061492A (ko) 2014-11-21 2016-06-01 삼성디스플레이 주식회사 휴대용 먼지 센서 및 이를 이용한 휴대전화
MX386778B (es) 2015-03-09 2025-03-19 Intekrin Therapeutics Inc Métodos para el tratamiento de enfermedad de hígado graso no alcohólico y/o lipodistrofia.
CA2981507A1 (en) 2015-04-07 2016-10-13 Intercept Pharmaceuticals, Inc. Pharmaceutical compositions for combination therapy
WO2017139588A1 (en) 2016-02-12 2017-08-17 Indiana University Research & Technology Corporation Lysosomal acid lipase and ppar gamma ligands as an immune therapies for cancer treatment
DK3468604T3 (da) 2016-06-08 2021-04-19 Support Venture Gmbh Farmaceutiske kombinationer til behandling af cancer
SG10202101500WA (en) 2016-08-18 2021-03-30 Intekrin Therapeutics Inc PPARγ AGONIST FOR TREATMENT OF BONE DISORDERS
EP3500268A4 (en) 2016-08-18 2020-04-15 Intekrin Therapeutics, Inc. PPARY AGONIST FOR THE TREATMENT OF CRAYFISH
CN110461318A (zh) 2016-09-13 2019-11-15 因特克林治疗股份有限公司 用chs-131治疗多发性硬化
US11350844B2 (en) 2016-11-23 2022-06-07 Mayo Foundation For Medical Education And Research System and method for generating nonalcoholic fatty liver disease activity score (NAS) using magnetic resonance elastography
JP7202892B2 (ja) 2017-01-11 2023-01-12 興和株式会社 非アルコール性脂肪性肝疾患の予防及び治療薬
US20190350918A1 (en) 2017-01-18 2019-11-21 Coherus Biosciences, Inc. PPARy AGONIST FOR TREATMENT OF HUNTINGTON'S DISEASE
WO2018187350A1 (en) 2017-04-03 2018-10-11 Coherus Biosciences Inc. PPARγ AGONIST FOR TREATMENT OF PROGRESSIVE SUPRANUCLEAR PALSY
CN110536682B (zh) 2017-04-18 2023-01-06 基恩菲特公司 依拉非诺或其衍生物与抗nash、抗纤维化或抗胆汁淤积药剂的组合
EA201992364A1 (ru) 2018-04-02 2020-03-23 Кохерус Байосайенсис Инк. АГОНИСТ PPARγ ДЛЯ ЛЕЧЕНИЯ ПРОГРЕССИРУЮЩЕГО НАДЪЯДЕРНОГО ПАРАЛИЧА
JP2022516509A (ja) 2018-12-31 2022-02-28 コヒラス・バイオサイエンシズ・インコーポレイテッド 非アルコール性脂肪性肝疾患（ｎａｆｌｄ）を治療するための組成物および方法
WO2020205027A1 (en) 2019-04-02 2020-10-08 Christos Mantzoros Compositions and methods to treat non-alcoholic fatty liver diseases (nafld)
WO2020205025A1 (en) 2019-04-04 2020-10-08 Coherus Biosciences, Inc. Compositions and methods to treat non-alcoholic fatty liver diseases (nafld)
WO2021076616A1 (en) 2019-10-15 2021-04-22 Coherus Biosciences, Inc. Compositions and methods to treat non-alcoholic fatty liver diseases (nafld)

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009151116A1 (ja) * 2008-06-13 2009-12-17 持田製薬株式会社 非アルコール性脂肪肝炎の予防／改善・治療薬
JP2013133312A (ja) * 2011-12-27 2013-07-08 Tropical Plant Resources Institute Inc 非アルコール性脂肪性肝疾患および／または非アルコール性脂肪肝炎の治療薬
WO2015005365A1 (ja) * 2013-07-10 2015-01-15 興和株式会社 非アルコール性脂肪性肝疾患治療剤

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
ANNALS OF INTERNAL MEDICINE, vol. 133, no. 4, JPN6019050742, 2000, pages 263 - 274, ISSN: 0004461600 *
BIOORGANIC & MEDICINAL CHEMISTRY, vol. 21, JPN6019050737, 2013, pages 979 - 992, ISSN: 0004461598 *
JOURNAL OF DIABETES AND ITS COMPLICATIONS, vol. 25, JPN6019050735, 2011, pages 151 - 158, ISSN: 0004461597 *
WORLD JOURNAL OF GASTROENTEROLOGY, vol. 14, no. 1, JPN6019050740, 2008, pages 22 - 28, ISSN: 0004461599 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021063088A (ja) * 2015-03-09 2021-04-22 インテクリン・セラピューティクス・インコーポレイテッド 非アルコール性脂肪肝疾患および／またはリポジストロフィーの処置のための方法
US11400072B2 (en) 2015-03-09 2022-08-02 Coherus Biosciences, Inc. Methods for the treatment of nonalcoholic fatty liver disease and/or lipodystrophy

Also Published As

Publication number Publication date
SG11201707276PA (en) 2017-10-30
HK1249847A1 (zh) 2018-11-16
US20200147036A1 (en) 2020-05-14
IL254282A0 (en) 2017-10-31
MX386778B (es) 2025-03-19
AU2016229982B2 (en) 2020-06-18
US10555929B2 (en) 2020-02-11
WO2016144862A1 (en) 2016-09-15
AU2016229982A1 (en) 2017-09-21
BR112017019170A2 (pt) 2018-07-10
EP3267994A4 (en) 2018-10-31
KR20220070057A (ko) 2022-05-27
TWI769976B (zh) 2022-07-11
EP3267994A1 (en) 2018-01-17
AU2020233626A1 (en) 2020-10-08
MA42450A (fr) 2018-05-23
SG10202103552XA (en) 2021-05-28
KR20180006881A (ko) 2018-01-19
AU2020233626B2 (en) 2022-06-02
US10772865B2 (en) 2020-09-15
CN107683135A (zh) 2018-02-09
US20160263098A1 (en) 2016-09-15
TW201639571A (zh) 2016-11-16
MX2021011949A (es) 2021-11-03
CA2979033A1 (en) 2016-09-15
US11400072B2 (en) 2022-08-02
MX2017011586A (es) 2017-10-26
EA201791982A1 (ru) 2020-02-17
US20200383945A1 (en) 2020-12-10
JP2021063088A (ja) 2021-04-22

Similar Documents

Publication Publication Date Title
US11400072B2 (en) Methods for the treatment of nonalcoholic fatty liver disease and/or lipodystrophy
EP3054940B1 (en) Compositions and methods for treating non-alcoholic steatohepatitis
JP6941109B2 (ja) Ｆｘｒアゴニストを使用するための方法
JP2020147585A (ja) 肝臓の疾患を治療するためのオメガ３脂肪酸とｓｇｌｔ−２阻害薬との併用剤
JP2019511478A (ja) Ｆｘｒアゴニストを使用するための方法
JP6999903B2 (ja) 脂肪肝に伴う希発排卵の治療
CN1925847A (zh) 增强欧司哌米芬生物利用度的方法
JP2022516509A (ja) 非アルコール性脂肪性肝疾患（ｎａｆｌｄ）を治療するための組成物および方法
KR20220016146A (ko) 담즙정체성 간 질환의 치료에서 사용하기 위한 fxr 효능제 및 피브레이트를 포함하는 제약 조성물
Zhou et al. Keverprazan, a novel potassium-competitive acid blocker: Single ascending dose safety, tolerability, pharmacokinetics, pharmacodynamics and food effect in healthy subjects
CN109689050A (zh) Fxr激动剂的新方案
KR20240073926A (ko) 간 용적을 감소시키기 위한 레스메티롬
TW202114654A (zh) 包含如sglt 1/2抑制劑的sglt抑制劑之治療
Lozano et al. Health complications of obesity during childhood and beyond
US20250161326A1 (en) Combination therapy
WO2019099509A1 (en) Use of a p2x7 receptor antagonist to treat an inflammatory disease or disorder
KR20240146052A (ko) 체중 감소 및 골격근 질량 보존 방법
EA042686B1 (ru) Способ лечения неалкогольного стеатогепатита
Trabazo Health complications of obesity during childhood and beyond
JP2025505632A (ja) 上昇したＨｂＡ１ｃを有する対象における体重減少の方法
CN110099686B (zh) 非酒精性脂肪性肝病的治疗
JP2025526746A (ja) 門脈圧亢進症を伴う肝硬変の治療のための併用療法
HK40012462B (en) Treatment of nonalcoholic fatty liver disease
HK40012462A (en) Treatment of nonalcoholic fatty liver disease

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190306

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190523

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20191218

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20191224

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200319

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20200818

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201217

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20201217

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20201218

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20210202

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20210209

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20210312

C211 Notice of termination of reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C211

Effective date: 20210316

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20211124

C13 Notice of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: C13

Effective date: 20220208

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20220412

C23 Notice of termination of proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C23

Effective date: 20220719

C03 Trial/appeal decision taken

Free format text: JAPANESE INTERMEDIATE CODE: C03

Effective date: 20220816

C30A Notification sent

Free format text: JAPANESE INTERMEDIATE CODE: C3012

Effective date: 20220816